Dark

Check out our Level2View

TLC
Taiwan Liposome Company, Ltd.
stock NASDAQ

Inactive

Sep 28, 2021

7.00USD0.000%(0.00)12,421

Pre-market

0.00USD-100.000%(-7.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Sep 8, 2021

04:50AM EDT TLC Announces Voluntary Delisting And Deregistration Of American Depositary Shares RTTNews

04:41AM EDT TLC Announces Voluntary Delisting and Deregistration of American GlobeNewswire Inc

Sep 2, 2021

08:20AM EDT The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab Benzinga

Aug 12, 2021

05:45AM EDT TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30, 2021 and provided a business update. GlobeNewswire Inc

Jul 13, 2021

10:13AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021 Benzinga

08:36AM EDT HC Wainwright & Co. Downgrades Taiwan Liposome Co to Neutral, Lowers Price Target to $7.5 Benzinga

Jul 5, 2021

06:16AM EDT TLC Announces Details of Stock Swap Transactions GlobeNewswire Inc

May 26, 2021

04:30AM EDT TLC and Zydus Enter Agreement to Launch AmphoTLC GlobeNewswire Inc

May 25, 2021

10:14AM EDT Mid-Morning Market Update: Markets Edge Higher; AutoZone Tops Q3 Expectations Benzinga

08:42AM EDT TLC Stock Jumps on India's Approval of Liposomal Amphotericin B As Black Fungus Treatment Benzinga

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

05:31AM EDT TLC Announced Approval of NDA of Liposomal Amphotericin B in India Benzinga

05:05AM EDT TLC Announces Approval of New Drug Application of Liposomal GlobeNewswire Inc

May 24, 2021

10:35AM EDT TLC Subsidiary, InspirMed, Sunday Morning Highlighted Presentation Of Data On Potential Advantages Of Inhalable Liposome Formulations Of Antiviral Drugs At International Society for Aerosols in Medicine Congress Benzinga

09:21AM EDT Taiwan Liposome's Inhalable Liposome Formulations of Antiviral Drugs Show Promise In COVID-19 Benzinga

May 23, 2021

09:00AM EDT InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 GlobeNewswire Inc

May 14, 2021

07:36AM EDT Taiwan Liposome Co Q1 EPS $(0.08) Up From $(0.10) YoY Benzinga

07:32AM EDT TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. GlobeNewswire Inc

May 3, 2021

05:15AM EDT TLC Earns Highest Ranking in Corporate Governance Evaluation Seven GlobeNewswire Inc

Apr 26, 2021

05:30AM EDT InspirMed to Present at the 23rd International Society for GlobeNewswire Inc

Mar 2, 2021

04:00AM EST TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Companys management team will be presenting at the following virtual investor conferences: GlobeNewswire Inc

Feb 5, 2021

04:15AM EST TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the fiscal year ended December 31, 2020 and provided a business update. GlobeNewswire Inc

Jan 4, 2021

05:00AM EST TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that its subsidiary, InspirMed Inc., has completed a round of financing, raising US$15 million in cash from strategic investors in exchange for subsidiary equity. GlobeNewswire Inc

Dec 28, 2020

04:00AM EST TLC Announces Full Patient Enrollment in EXCELLENCE Trial of GlobeNewswire Inc

Dec 18, 2020

04:00AM EST Patient enrollment of EXCELLENCE pivotal trial reaches 98% GlobeNewswire Inc

Nov 3, 2020

07:38AM EST TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program by GlobeNewswire Inc

Oct 28, 2020

04:51AM EDT TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the third quarter ending September 30, 2020, and provided a business update. GlobeNewswire Inc

Oct 21, 2020

04:45AM EDT TLC Announces the Appointment of Thomas H. Bliss, Jr., MBA, as GlobeNewswire Inc

Oct 14, 2020

05:27AM EDT TLC Announced it Enrolled First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19) Benzinga

04:41AM EDT TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the first subject has been enrolled in the Phase I clinical trial of TLC19 for treatment or prophylaxis of Coronavirus disease 2019 (COVID-19). GlobeNewswire Inc

Oct 7, 2020

02:24PM EDT Why Taiwan Liposome's Stock Is Trading Higher Today Benzinga

10:10AM EDT Mid-Morning Market Update: Markets Open Higher; RPM International Profit Beats Views Benzinga

10:09AM EDT Shares of Taiwan Liposome Company, Ltd. (TLC) jumped over 30% on Wednesday morning after the company received approval in Australia to initiate phase 1 trial of COVID-19 treatment. RTTNews

12:21AM EDT TLC Gets Australian And Taiwan Approval To Begin Phase I Clinical Trial Of TLC19 Inhalable Liposomal Hydroxychloroquine RTTNews

Oct 6, 2020

11:54PM EDT TLC Receives Australian and Taiwan Approval to Initiate Phase I GlobeNewswire Inc

Sep 21, 2020

04:45AM EDT TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that President Mr. George Yeh and Chief Medical Officer Dr. George Spencer-Green, MD, will be presenting at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Wednesday, September 23, 2020 at 9:10am ET. GlobeNewswire Inc

Sep 11, 2020

04:45AM EDT TLC to Present at Cantor Virtual Global Healthcare Conference GlobeNewswire Inc

Sep 9, 2020

05:00AM EDT TLC to Present at HC Wainwright & Co. 22nd Annual Global GlobeNewswire Inc

Sep 3, 2020

05:00AM EDT TLC to Present at Bairds 2020 Global Healthcare GlobeNewswire Inc

Aug 26, 2020

05:40AM EDT TLC and 3SBio Announce Acceptance of Marketing Authorization GlobeNewswire Inc

Aug 14, 2020

03:03PM EDT Mid-Afternoon Market Update: PaySign Drops After Q2 Results; Textainer Group Shares Climb Benzinga

12:17PM EDT Mid-Day Market Update: Dow Turns Higher; Mesoblast Shares Surge Benzinga

10:20AM EDT Mid-Morning Market Update: Markets Edge Lower; Applied Materials Tops Q3 Expectations Benzinga

10:18AM EDT Shares of Taiwan Liposome Co. Ltd. (TLC) are gaining almost 60 percent in Friday's morning trade at $8.15. RTTNews

07:05AM EDT Taiwanese specialty pharmaceutical company Taiwan Liposome Co. Ltd. (TLC) announced Friday the submission of an Investigational New Drug (IND) Application to the Taiwan Food and Drug Administration (TFDA) for TLC19 Hydroxychloroquine Liposome Inhalation Suspension for the treatment of coronavirus (COVID-19) disease. RTTNews

06:36AM EDT TLC Submits IND Application For TLC19 Inhalable Liposomal Hydroxychloroquine For COVID-19 RTTNews

06:30AM EDT 1% of oral dose for 30-fold lung exposure and reduced cardiotoxicityA cost-effective, easily accessible, user-friendly potential treatment/prevention option GlobeNewswire Inc

Aug 5, 2020

05:00AM EDT TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ending June 30, 2020, and provided a business update. GlobeNewswire Inc

Jul 20, 2020

05:11AM EDT 80 Biggest Movers From Friday Benzinga

Jul 17, 2020

05:08AM EDT 64 Biggest Movers From Yesterday Benzinga

Jul 15, 2020

10:13AM EDT Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Beats Q2 Expectations Benzinga

08:25AM EDT Shares of Taiwan Liposome Co. Ltd. (TLC) have been trading in the range of $2.48 - $8.54 for the past one year, and closed Tuesday's trade at $6.50, up 10 cents or 1.56%. TLC is currently trading at $8.50, up $2.27 or 36.44% in the pre-market session. RTTNews

07:24AM EDT TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that a pre-print version of a manuscript on TLCs strategy to treat COVID-19 disease with targeted delivery of inhalable liposomal hydroxychloroquine has been made publicly available. GlobeNewswire Inc

Share